32.65

0.28% 0.09

After Hours: 32.85 0.20 +0.61%

Viking Therapeutics Inc (VKTX)

Overview News Price History Option Chain Financials Why VKTX Down? Discussions Forecast

Viking Therapeutics Inc stock is traded at $32.65, with a volume of 4.36M. It is up +0.28% in the last 24 hours and down -30.09% over the past month. Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Previous Close:

$32.56

Open:

$32.94

24h Volume:

4.36M

Relative Volume:

1.00

Market Cap:

$3.64B

Revenue:

Net Income/Loss:

$-99.15M

P/E Ratio:

-35.11

EPS:

-0.93

Net Cash Flow:

$-74.25M

1W Performance:

-16.94%

1M Performance:

-30.09%

6M Performance:

-34.49%

1Y Performance:

+52.43%

1-Day Range:

$32.56

$34.24

1-Week Range:

$32.51

$39.40

52-Week Range:

$20.47

$99.41

Viking Therapeutics Inc Stock (VKTX) Company Profile

Name

Viking Therapeutics Inc

Sector

Healthcare (1174)

Industry

Biotechnology (684)

Phone

858-704-4660

Address

9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA

Employee

Twitter

@viking_vktx

Next Earnings Date

2024-10-23

Latest SEC Filings

VKTX's Discussions on Twitter

Compare VKTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VKTX Viking Therapeutics Inc	32.65	3.64B	0	-99.15M	-74.25M	-0.93
VRTX Vertex Pharmaceuticals Inc	422.00	108.68B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	681.58	74.90B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	640.52	38.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	246.27	31.76B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	111.93	26.83B	3.30B	-501.07M	1.03B	-2.1146

Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-02-24	Initiated	Piper Sandler	Overweight
Nov-22-24	Initiated	B. Riley Securities	Buy
Nov-04-24	Reiterated	H.C. Wainwright	Buy
Sep-11-24	Initiated	JP Morgan	Overweight
Jun-27-24	Initiated	Morgan Stanley	Overweight
May-16-24	Upgrade	Raymond James	Outperform → Strong Buy
Mar-26-24	Reiterated	Oppenheimer	Outperform
Mar-07-24	Initiated	Jefferies	Buy
Feb-28-24	Reiterated	Oppenheimer	Outperform
May-31-23	Resumed	ROTH MKM	Buy
Mar-28-23	Reiterated	Maxim Group	Buy
Mar-17-23	Initiated	Stifel	Buy
Jul-29-21	Resumed	BTIG Research	Buy
May-25-21	Downgrade	Raymond James	Strong Buy → Outperform
Jun-05-20	Initiated	BMO Capital Markets	Outperform
May-05-20	Initiated	Chardan Capital Markets	Buy
May-01-20	Initiated	BTIG Research	Buy
Jul-16-19	Initiated	Oppenheimer	Outperform
Jun-25-19	Initiated	Stifel	Buy
Mar-29-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Mar-14-19	Reiterated	Maxim Group	Buy
Feb-22-19	Initiated	SVB Leerink	Mkt Perform
Dec-12-18	Initiated	B. Riley FBR	Buy
Nov-19-18	Upgrade	Raymond James	Outperform → Strong Buy
Sep-18-18	Reiterated	H.C. Wainwright	Buy
Sep-18-18	Reiterated	Maxim Group	Buy
Sep-18-18	Reiterated	Raymond James	Outperform
Jul-20-18	Initiated	SunTrust	Buy
Jun-28-18	Initiated	Raymond James	Outperform
Jun-01-18	Reiterated	Laidlaw	Buy
May-31-18	Reiterated	Maxim Group	Buy
Mar-26-18	Resumed	H.C. Wainwright	Buy
Nov-28-17	Reiterated	Maxim Group	Buy
Nov-21-17	Initiated	ROTH Capital	Buy

View All

Viking Therapeutics Inc Stock (VKTX) Latest News

02:34 AM

Viking Therapeutics: The Turning Point Is Not Here Yet - Seeking Alpha

02:34 AM

09:56 AM

Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views? - Zacks Investment Research

09:56 AM

02:00 AM

Shelton Wealth Management LLC Purchases New Stake in Viking Therapeutics, Inc. (NASDAQ:VKTX) - MarketBeat

Jan 19, 2025

Jan 18, 2025

Viking Therapeutics (NASDAQ:VKTX) Receives "Buy" Rating from HC Wainwright - MarketBeat

Jan 18, 2025

Jan 17, 2025

12 Biotech Stocks with the Biggest Upside Potential - Insider Monkey

Jan 17, 2025

Viking Therapeutics (NASDAQ:VKTX) Sees Strong Trading VolumeWhat's Next? - MarketBeat

Jan 17, 2025

Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today - sharewise

Jan 17, 2025

Viking Therapeutics (NASDAQ:VKTX) Trading Down 4.8%Here's What Happened - MarketBeat

Jan 17, 2025

Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs - AOL

Jan 17, 2025

Why Viking Therapeutics (VKTX) Is the Biotech Stock with Biggest Upside Potential - MSN

Jan 17, 2025

We Asked Retail How Viking Therapeutics Can Restore Investor Confidence: Majority Say Pursue Buyout Talks - MSN

Jan 17, 2025

Jan 16, 2025

Here's How Much $1000 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today - Benzinga

Jan 16, 2025

Jan 15, 2025

NVO, VKTX Stocks Fall as Lilly's Zepbound, Mounjaro Sales Slow Down - Yahoo Finance

Jan 15, 2025

Jan 14, 2025

Viking Therapeutics posts positive results for oral weight-loss drug. Analysts remain unanimous the stock’s a buy. - MSN

Jan 14, 2025

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc.VKTX - PR Newswire

Jan 14, 2025

Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday - MSN

Jan 14, 2025

Viking Therapeutics Becomes Oversold (VKTX) - Nasdaq

Jan 14, 2025

Jan 13, 2025